Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

Kristen M. Sanfilippo, Suhong Luo, Tzu Fei Wang, Mark Fiala, Martin Schoen, Tanya M. Wildes, Joseph Mikhael, Nicole M. Kuderer, David C. Calverley, Jesse Keller, Theodore Thomas, Kenneth R. Carson, Brian F. Gage

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk of VTE by the presence of risk factors. The National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. We sought to develop and validate a risk prediction score for VTE in MM and to evaluate the performance of the current IMWG/NCCN guidelines. Using 4446 patients within the Veterans Administration Central Cancer Registry, we used time-to-event analyses to develop a risk score for VTE in patients with newly diagnosed MM starting chemotherapy. We externally validated the score using the Surveillance, Epidemiology, End Results (SEER)-Medicare database (N = 4256). After identifying independent predictors of VTE, we combined the variables to develop the IMPEDE VTE score (Immunomodulatory agent; Body Mass Index ≥25 kg/m2; Pelvic, hip or femur fracture; Erythropoietin stimulating agent; Dexamethasone/Doxorubicin; Asian Ethnicity/Race; VTE history; Tunneled line/central venous catheter; Existing thromboprophylaxis). The score showed satisfactory discrimination in the derivation cohort, c-statistic = 0.66. Risk of VTE significantly increased as score increased (hazard ratio 1.20, P = <.0001). Within the external validation cohort, IMPEDE VTE had a c-statistic of 0.64. For comparison, when evaluating the performance of the IMWG/NCCN guidelines, the c-statistic was 0.55. In summary, the IMPEDE VTE score outperformed the current IMWG/NCCN guidelines and could be considered as the new standard risk stratification for VTE in MM.

Original languageEnglish
Pages (from-to)1176-1184
Number of pages9
JournalAmerican journal of hematology
Volume94
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Dive into the research topics of 'Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score'. Together they form a unique fingerprint.

Cite this